Press "Enter" to skip to content

Pulmonary Arterial Hypertension (PAH) Market, By Drug Class (Prostacyclin and Analogs, SGC Stimulators, ERA and Phosphodiesterase-5) and Geography (NA, EU, APAC, and RoW)-Analysis, Share, Trends, Size, & Forecast From 2014-2025

Ask for Sample/Enquiry and details report @ WMR Arterial Hypertension (PAH) Ma#sample

WMR-Western Market Research has recently published a comprehensive and exclusive research report, which is an intelligent study covering all key segments. This research report provides breakthrough inputs and insights on market related factors like size, competition, trends, analysis, forecasts etc. The study encompasses primary and secondary data sources along with quantitative and qualitative practices thus assuring data accuracy.

The pulmonary arterial hypertension (PAH) market is estimated to represent a global market of USD 5.38 billion by 2017 with growth rate of 5.6%.

Ask for Sample/Enquiry and details report @ WMR Arterial Hypertension (PAH) Ma#inquiry

Market Dynamics

According to the World Health Organization (WHO), pulmonary arterial hypertension is a debilitating condition, characterized by the elevated pulmonary vascular resistance and pulmonary arterial pressure. The condition may lead to the failure of right ventricular or patients death. PAH can be hereditable, idiopathic, or associated with conditions such as congenital heart disease, connective tissue disease, hypertension, and HIV infection. PAH is categorized under rate disease as the prevalence of this disorder is very low, with an estimated prevalence around 15 to 50 cases per million population. However, the prevalence of this disorder is increasing during the past few years owing to the risk factors such as smoking, tobacco consumption, sedentary lifestyle, and other idiopathic conditions.

The market for Pulmonary Arterial Hypertension is primarily driven by the favourable government initiatives for the development of orphan drugs. The government provides benefits in terms of enhanced patent protection term, tax incentives etc. Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983 are the two important acts which facilitate the distribution and ethical usage of orphan therapeutics. For instance, The ODA facilitates tax credits up to 50.0% of overall research cost, protocol assistance, waiver in U.S. FDA fees and clinical tax incentives. This fact would, in turn, encourage key players to invest in this industry, augmenting the market growth to great extent.

Click for BUY NOW and ask for lucrative Discount @ WMR

Furthermore, growing awareness coupled with a well-planned reimbursement structure resulted in superlative diagnosis rate for PAH conditions across the globe, driving the industry growth. However, patent expiry of blockbuster therapeutics pulls back the industry growth to some extent. For instance, drugs such as Uptravi (2023), Orenitram (2024), and Opsumit are expired in near future. Additionally, this condition is often not diagnosed in a timely manner owing to its symptoms are subtle, and is confused with many other disease conditions. This fact would, in turn, further reduce the number of patients undergoing PAH treatment, hampering the market growth to some extent.

Drug Class Takeaway

In terms of drug class, the industry is categorized as Prostacyclin and Analogs, Soluble Guanylyl Cyclase (SGC) Stimulators, Endothelin receptor antagonist (ERA) and Phosphodiesterase-5. An ERA dominated the market with a substantial share of over 40% throughout the study period. On another hand, drugs targeting the prostacyclin pathway reported global sales of over USD 2.3 billion in 2017. Iloprost (Ventavis from Actelion), Epoprostenol (Veletri from Actelion and Flolan from GSK), Treprostinil (Tyvaso, Remodulin, and Orenitram from United Therapeutics) are some of the prostacyclin analogs approved by the U.S. FDA for the treatment of PAH. SGC stimulators are the lowest revenue generating drug class owing to the availability of other effective therapeutics.

Global Pulmonary Arterial Hypertension Market, by Drug Class, 2017 vs 2025

Regional Takeaway

Geographically, the industry is categorized into North America, Europe, Asia Pacific and Rest of the World. Developed regions such as North America and Europe accounted for the highest share of the global market.

Key Vendor Takeaway

Companies such as Pfizer, Inc., GlaxoSmithKline, Novartis, Bayer, and Merck are some of the prominent participants in the global Pulmonary Arterial Hypertension market. Apart of it, the presence of small players is noticeable too. For instance, Actelion Pharmaceuticals is developing a Macitentan drug for pediatric PAH. The company has initiated phase III (titled as Tomorrow) study which will evaluate the effect of macitentan on children with PAH. Also, in October 2015, Gilead Sciences, Inc.s new combination treatment of Tadalafil and Letairis is approved by the U.S. FDA. Such facts will further help key players to enhance their market presence.

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year-2014 & 2016
Base Year-2017
Estimated Year-2018
Projected Year-2025

Traders, Distributors, and Suppliers
Government and Regional Agencies and Research Organizations

The scope of this report covers the market by its major segments, which include as follows:


Prostacyclin and Analogs
Soluble Guanylyl Cyclase (SGC) Stimulators
Endothelin receptor antagonist (ERA)

North America
Rest of Europe
Asia Pacific
Rest of APAC
Rest of the World
Middle East and Africa
Latin America

Click to know more about product @ WMR Arterial Hypertension (PAH) Ma


For More info. Contact.
Jeffrey Daniel (Marketing & Sales)
Phone No (US). +1315-359-4245
Phone No (IN) +91 7757044254
Visit Our Website-
Connect with us – LinkedIn | Twitter| Facebook

Be First to Comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *